Aprea Therapeutics Inc. (NASDAQ:APRE) price closed lower on Friday, October 01, dropping -2.64% below its previous close.
A look at the daily price movement shows that the last close reads $5.11, with intraday deals fluctuated between $4.76 and $5.12. Taking into account the 52-week price action we note that the stock hit a 52-week high of $30.99 and 52-week low of $3.17. The stock added 5.18% on its value in the past month.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Aprea Therapeutics Inc., which has a market valuation of $108.31 million, is expected to release its quarterly earnings report Mar 16, 2021. Analysts tracking APRE have forecast the quarterly EPS to shrink by -0.45 per share this quarter, while the same analysts predict the annual EPS to hit -$1.73 for the year 2021 and up to -$1.63 for 2022. In this case, analysts estimate an annual EPS growth of 31.60% for the year and 5.80% for the next year.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give APRE a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as Hold.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 5 analysts have assigned APRE a recommendation rating as follows: 3 rate it as a Hold; 0 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Aprea Therapeutics Inc. (APRE) stock as Underweight, with 2 recommending Sell. In general, analysts have rated the stock Underweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that APRE’s price is at present 5.47% off the SMA20 and 14.29% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 58.48, with weekly volatility standing at 10.77%. The indicator jumps to 8.24% when calculated based on the past 30 days. Aprea Therapeutics Inc. (NASDAQ:APRE)’s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 0.39. Considering analysts have assigned the stock a price target range of $3.00-$5.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $4.00. Based on this estimate, we see that current price is roughly 39.64% off the estimated low and -0.6% off the forecast high. Investors will no doubt be excited to see the share price rise to $4.00, which is the median consensus price, and at that level APRE would be 19.52% from current price.
An analysis of the Aprea Therapeutics Inc. (NASDAQ:APRE) stock in terms of its daily trading volume indicates that the 3-month average is 1.86 million. However, this figure increases on the past 10-day timeline to an average of 2.18 million.
Current records show that the company has 21.19M in outstanding shares. The insiders’ percentage holdings are 2.40% of outstanding shares while the percentage share held by institutions stands at 43.00%. The stats also highlight that short interest as of Apr 14, 2021, stood at 1.67 million shares, which puts the short ratio at the time at 1.27. From this we can glean that short interest is 7.90% of company’s current outstanding shares. Notably, we see that shares short in April rose slightly given the previous month’s figure stood at 1.31 million. But the 1.12% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.